However, the mutations especially the T315I mutation in BCR-ABL kinase domain have led to the development of drug resistance and hindered the success of imatinib or second generation TKIs in the treatment of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.